ALCAM and neuroblastoma: Among them, ALCAM, BTBD9, CACNA2D3, DST, EPB41L4A, FGD6, GMEB1, IGSF3 and KIF1B were commonly changed in MYCN non-amplified younger neuroblastoma patients in TARGET, GSE49710 and GSE85047 datasets (Fig. 4c).